Table 2.
Agreement for cardiovascular and noncardiovascular conditions
| Co-Morbidity | Number | Yes/Yes | No/No | Yes/No | No/Yes | Crude Agreement | Positive Agreement | Negative Agreement | κ |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | |||||||||
| Arrhythmia | 191 | 103 | 35 | 36 | 17 | 72% | 80% | 57% | 0.37 |
| Dyslipidemia* | 223 | 94 | 71 | 34 | 24 | 74% | 76% | 71% | 0.48 |
| Hypertension | 224 | 127 | 49 | 26 | 22 | 79% | 84% | 67% | 0.51 |
| Stent | 221 | 15 | 185 | 21 | 0 | 90% | 59% | 95% | 0.54 |
| Myocardial infarction | 196 | 50 | 123 | 16 | 7 | 88% | 81% | 91% | 0.73 |
| Coronary bypass surgery | 225 | 39 | 183 | 3 | 0 | 99% | 97% | 99% | 0.95 |
| Defibrillator/pacemaker | 221 | 140 | 77 | 3 | 1 | 98% | 99% | 98% | 0.96 |
| Noncardiovascular | |||||||||
| Peptic ulcer disease | 218 | 1 | 198 | 4 | 15 | 91% | 10% | 95% | 0.06 |
| Peripheral arterial disease | 230 | 4 | 176 | 0 | 50 | 78% | 14% | 88% | 0.11 |
| Lung disease | 203 | 29 | 113 | 39 | 22 | 70% | 49% | 79% | 0.28 |
| Osteoarthritis | 215 | 10 | 174 | 23 | 8 | 86% | 39% | 92% | 0.32 |
| Liver disease | 225 | 3 | 212 | 2 | 8 | 96% | 38% | 98% | 0.36 |
| Thyroid | 214 | 26 | 174 | 7 | 7 | 93% | 79% | 96% | 0.75 |
| Cancer | 229 | 34 | 185 | 8 | 2 | 96% | 87% | 97% | 0.85 |
| Diabetes mellitus | 228 | 69 | 144 | 6 | 9 | 93% | 90% | 95% | 0.85 |
| HIV infection | 182 | 1 | 181 | 0 | 0 | 100% | 100% | 100% | 1.00 |
| Behavioral | |||||||||
| Excess alcohol use | 218 | 3 | 200 | 3 | 12 | 93% | 29% | 96% | 0.26 |
| Cocaine abuse | 224 | 11 | 198 | 14 | 1 | 93% | 59% | 96% | 0.56 |
| Tobacco | 203 | 64 | 108 | 31 | 0 | 85% | 81% | 87% | 0.69 |
Kappa p values <0.001 for all conditions except peripheral arterial disease (p = 0.006) and peptic ulcer disease (p = 0.27). All yes and no citations are by patient report first, followed by EHR documentation.
*
Use of lipid-lowering medications or fulfilling the National Cholesterol Education Program Adult Treatment Panel III criteria.